GGHC
RNAM

Gilder Gagnon Howe & Co’s Avidity Biosciences RNAM Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,444
Closed -$298K – 258
2022
Q4 		$298K Buy
+13,444
New +$200K 0.01% 227
2022
Q1 		– Sell
-30,983
Closed -$736K – 341
2021
Q4 		$736K Sell
30,983
-126
-0.4% -$3.01K ﹤0.01% 309
2021
Q3 		$766K Buy
31,109
+16,539
+114% +$359K ﹤0.01% 331
2021
Q2 		$360K Buy
14,570
+1,414
+11% +$32.9K ﹤0.01% 356
2021
Q1 		$287K Buy
13,156
+3,361
+34% +$82.3K ﹤0.01% 333
2020
Q4 		$250K Sell
9,795
-33
-0.3% -$962 ﹤0.01% 296
2020
Q3 		$277K Sell
9,828
-172
-2% -$4.97K ﹤0.01% 297
2020
Q2 		$283K Buy
+10,000
New +$288K ﹤0.01% 267

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Gilder Gagnon Howe & Co's RNAM Position: Q1 2023 in Review

Gilder Gagnon Howe & Co sold out of Avidity Biosciences (RNAM) in Q1 2023, closing a stake of 13,444 shares — an estimated $298K sold.

Gilder Gagnon Howe & Co first reported a position in RNAM in Q2 2020 and held it in 8 quarters. The position peaked at $766K in Q3 2021. 139 funds tracked by Wall St. Rank hold RNAM as of Q1 2023.

  • Gilder Gagnon Howe & Co reported no remaining Avidity Biosciences position as of Q1 2023 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 13,444 Avidity Biosciences shares in Q1 2023, an estimated $298K.
  • Gilder Gagnon Howe & Co first reported a position in Avidity Biosciences in Q2 2020 and held it in 8 quarters.
  • Gilder Gagnon Howe & Co's Avidity Biosciences position peaked at $766K in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2023, filed 15 May 2023.